What is Novo Nordisk net worth?
Andrew Walker
Updated on February 09, 2026
What is Novo Nordisk net worth?
Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares….Novo Nordisk.
| Type | Aktieselskab |
|---|---|
| Total assets | DKK 125.612 billion (2019) |
| Total equity | DKK 57.593 billion (2019) |
| Number of employees | 43,258 (2019) |
| Website |
Is Novo Nordisk ethical?
Promote bioethical awareness in Novo Nordisk. Operate by high ethical global standards in research involving people, animals, human materials and gene technology. Require adherence to high ethical standards by our external partners, contract research organisations and suppliers, and monitor their performance.
What is market capitalization of a company?
Market capitalization refers to the total dollar market value of a company’s outstanding shares of stock. Commonly referred to as “market cap,” it is calculated by multiplying the total number of a company’s outstanding shares by the current market price of one share.
Who owns Novo Nordisk?
Novo Holdings A/S
Novo Nordisk Foundation owns Novo Holdings A/S, a holding company and majority shareholder of Novo Nordisk. In 2020 the foundation awarded $0.91 billion (5.54 billion DKK) and paid out $0.75 billion (4.6 billion DKK) worth of grants….Novo Nordisk Foundation.
| Novo Nordiskm Foundation |
|---|
| Website |
Does Novo Nordisk pay well?
The average Novo Nordisk salary ranges from approximately ₹3.7 Lakhs per year for a Professional 1 to ₹ 39.6 Lakhs per year for a Senior Manager. The highest-paying job at Novo Nordisk is a Senior Manager with a salary of ₹39.6 Lakhs per year. The top 10% of employees earn more than ₹19 lakhs per year.
Who is the largest producer of insulin?
Novo Nordisk
Novo Nordisk – As the world’s largest producer of insulin,… | Facebook.
What insulin does Novo Nordisk make?
(a) FIASP® (insulin aspart injection) 100 U/mL, NOVOLOG® (insulin aspart injection) 100 U/mL, NOVOLOG® MIX 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 U/mL: Pay as little as (“PALA”) $25 per 30-day, $50 per 60-day, or $75 per 90-day supply for the first brand for up to 24 months from …
Is Novo Nordisk A good company to work for?
82% of employees at Novo Nordisk Inc. say it is a great place to work compared to 59% of employees at a typical U.S.-based company.
What is market capitalization and why is it important?
Market cap measures what a company is worth on the open market, as well as the market’s perception of its future prospects, because it reflects what investors are willing to pay for its stock. Large-cap companies are typically firms with a market value of $10 billion or more.
Who is the CEO of Novo Nordisk?
Lars Fruergaard Jørgensen (Jan 1, 2017–)
Novo Nordisk/CEO
Novo Nordisk CEO Lars Fruergaard Jørgensen discusses first-quarter earnings and the outlook for the North American region for the Danish pharmaceutical company.
Why is insulin so cheap in Canada?
Canada, like many other industrialized countries, has price controls on the cost of pharmaceuticals. The Patented Medicine Prices Review Board strictly regulates the price of patented medicine sold in Canada so that it is not excessive.
What is the stock price of Novo Nordisk?
Shares of Novo Nordisk have gained 10.8% so far this year, while the SPDR S&P Pharmaceuticals ETF has gained 3%. The Dow Jones Industrial Average has gained 11.8% and the S&P 500 has gained 15.3%.
What’s the brand name for Novo Nordisk wegovy?
It will be marketed by the brand name of Wegovy. Novo Nordisk A/S (NYSE: NVO) has gained U.S. approval for a once-weekly semaglutide 2.4 mg injection, dubbed Wegovy, for chronic weight management.
Why did Novo Nordisk get a regulatory nod?
The regulatory nod is a big win for Novo, which has seen its core insulin business suffer from tough competition, prompting it to turn toward newer diabetes and obesity drugs to revive growth.
When does Novo Nordisk start share repurchase programme?
Bagsværd, Denmark, 7 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”).
